The company's oncology therapeutics are designed for antigen-independent intracellular drug delivery, enabling highly potent drugs and combination therapies that expand the efficacy of existing anticancer agents to larger, high unmet need populations. Cybrexa's alphalex™ technology is a novel antigen-independent peptide drug conjugate platform that aims to revolutionize the standard of care in oncology, consisting of a pHLIP® peptide, linker, and small molecule anti-cancer agent. Early clinical trials of the company's lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer.